natgillin/translations-raw huggingface dataset:
Trastuzumab and anthracyclines should not be given concurrently in combination in the MBC setting. 
Pri zdravljenju metastatskega raka dojk kombinacije trastuzumaba in antraciklinov ne smemo dajati sočasno.
NAME OF THE MEDICINAL PRODUCT Ogivri 150 mg powder for concentrate for solution for infusion trastuzumab 
Ogivri 150 mg prašek za koncentrat za raztopino za infundiranje trastuzumab
Powder for concentrate for solution for infusion (powder for concentrate). 
FARMACEVTSKA OBLIKA prašek za koncentrat za raztopino za infundiranje (prašek za koncentrat) Bel do rahlo rumen liofiliziran prašek.
• hair loss 
• izguba telesne mase
If you get any side effects, talk to your doctor, pharmacist or nurse. 
Če opazite katerega koli izmed neželenih učinov, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
• respiratory distress 
• motnje delovanja pljuč
N 
SN:
Asthenia 
ZDRAVILOM
Common side effects: may affect up to 1 in 10 people 
Pogosti neželeni učinki, ki se lahko pojavijo pri največ 1 od 10 bolnikov:
• bruising 
• srbenje
Acute pulmonary oedema 
+akutni pljučni edem neznano
After a median follow-up of 12 months, the hazard ratio (HR) for disease free survival (DFS) was 0.54 (95 % CI 0.44, 0.67) which translates into an absolute benefit, in terms of a 2-year disease-free survival rate, of 7.6 percentage points (85.8 % versus 78.2 %) in favour of the trastuzumab arm. 
Po mediano 12-mesečnem spremljanju je bilo razmerje ogroženosti za preživetje brez bolezni 0,54 (95-% IZ: 0,44; 0,67).
Ogivri is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC): - as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. 
Zdravilo Ogivri je indicirano za zdravljenje odraslih bolnikov s HER2-pozitivno metastatsko obliko raka dojk:
Recurrence-free survival - No. patients with event - No. patients without event P-value versus Observation Hazard Ratio versus Observation 
Post-hoc eksplorativna analiza z dogodki preživetja brez bolezni in simptomatskimi srčnimi dogodki Dolgoročno spremljanje** Razmerje ogroženosti (95-% IZ)
Retinal haemorrhage 
• dihalna stiska
• lung disorders 
• bolezni ledvic
Contusion 
Sledljivost
ATC vet code: QI07AD08. 
Oznaka ATC vet: QI07AD08.
Komenského 212, 683 23 Ivanovice na Hané, CZECH REPUBLIC 
683 23 Ivanovice na Hané, ČEŠKA
Do not mix with any veterinary medicinal product except those mentioned in section 4.8. 
Ne mešajte z nobenimi drugimi zdravili, razen s tistimi navedenimi v poglavju 4.8.
Duration of immunity: At least one year following the primary vaccination course. 
Trajanje imunosti: Vsaj eno leto po osnovnem cepljenju.
However, due to the low pathogenicity of this strain, it is not necessary to keep vaccinated dogs separated from non-vaccinated dogs. 
Zaradi nizke patogenosti teh sevov ločevanje cepljenih psov od necepljenih ni potrebno.
MARKETING AUTHORISATION NUMBER(S) EU/2/14/168/001 
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/14/168/001
Overdose(symptoms, emergency procedures, antidotes): 
Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi):
4.2 Indications for use, specifying the target species Active immunisation of dogs from 6 weeks of age: 
4.2 Indikacije za uporabo pri ciljnih živalskih vrstah Aktivna imunizacija psov, starejših od 6 tednov:
Shake well and administer immediately the entire contents (1 ml) of the reconstituted product. 
Pred uporabo dobro pretresite in takoj injicirajte živali celotno rekonstituirano vsebino (1 ml).
The vaccine is intended for the active immunisation of healthy puppies and dogs against disease caused by canine parainfluenza virus. 
Cepivo je namenjeno aktivni imunizaciji pasjih mladičev in odraslih psov proti boleznim, ki jih povzroča virus pasje parainfluence.
3 weeks after completion of the primary course. 
3 tedne po zaključku osnovnega cepljenja.
Re-vaccination scheme: A single dose of Versican Plus Pi to be given annually. 
Ponovno cepljenje: Enkratni odmerek Versican Plus Pi letno.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product other than Versiguard Rabies and Versican Plus L4. 
Ni podatkov o varnosti ter učinkovitosti ob uporabi tega cepiva s katerim koli drugim zdravilom za uporabo v veterinarski medicini kot je Versiguard Rabies in Versican Plus L4.
Once mixed, the contents of the vial should appear a pink/red or yellowish colour with a slight opalescence. 
Po zmešanju mora vsebina viale izgledati rožnato/rdeče ali rumenkaste barve z rahlo opaloscenco.
Although the efficacy of the rabies fraction has been demonstrated following administration at 12 weeks, at the discretion of the veterinary surgeon, in case of need, dogs younger than 8 weeks can be vaccinated with Versican Plus Pi mixed with Versiguard Rabies as the safety of this association has been demonstrated in 6 week old dogs. 
Čeprav je bila učinkovitost komponente proti steklini dokazana pri dajanju v starosti 12 tednov, se v primeru, da je to potrebno in ob presoji veterinarja, s cepivom Versican Plus Pi, ki se ga zmeša s cepivom Versiguard Rabies lahko cepi pse, mlajše od 8 tednov, ker je bila varnost te kombinacije v starosti 6 tednov pri psih dokazana.
If protection against Leptospira is required, dogs can be vaccinated with two doses of Versican Plus Pi mixed with Versican Plus L4 3-4 weeks apart from 6 weeks of age: The contents of a single vial of Versican Plus Pi should be reconstituted with the contents of a single vial of Versican Plus L4 (instead of the solvent). 
Če je treba pse zaščititi pred leptospirozo lahko pse cepimo z dvema odmerkoma Versican Plus Pi, ki ga zmešamo z Versican Plus L4 v razmaku 3-4 tednov od starosti 6 tednov naprej: Vsebino viale zdravila Versican Plus Pi je treba rekonstituirati z vsebino viale zdravila Versican Plus L4 (namesto vehikla).
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 04/07/2014. 
Datum pridobitve dovoljenja za promet: 04/07/2014.
Solvent: clear colourless liquid. 
vehikel: bistra brezbarvna tekočina.
Interaction with other medicinal products and other forms of interaction: No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product other than Versiguard Rabies and Versican Plus L4. 
4.8 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Ni podatkov o varnosti ter učinkovitosti ob uporabi tega cepiva s katerim koli drugim zdravilom za uporabo v veterinarski medicini razen za Versiguard Rabies in Versican Plus L4.
Incompatibilities: Do not mix with any other veterinary medicinal product other than those mentioned above. 
Ne mešajte z drugimi zdravili kot s tistimi navedenimi zgoraj.
The live attenuated virus vaccine strain CPiV may be shed by vaccinated animals following vaccination. 
Cepljene živali lahko po cepljenju izločajo žive atenuirane vakcinalne seve CpiV.
Hypersensitivity reactions (e.g. gastrointestinal signs such as diarrhoea and vomiting, anaphylaxis, angioedema, dyspnoea, circulatory shock, collapse) may occur rarely. 
Preobčutljivostne reakcije (gastrointestinalni znaki, kot so driska in bruhanje, anafilaksa, angioedem,
First dose: Versican Plus Pi from 8-9 weeks of age. 
Prvi odmerek: Versican Plus Pi od starosti 8-9 tednov naprej
Type 1 glass vial containing 1 ml of solvent closed with a chlorobutyl rubber stopper and aluminium cap. 
Viala iz stekla tipa I, ki vsebuje 1 ml vehikla, zaprta z zamaškom iz klorobutilne gume in aluminijasto zaporko.
EXP {month/year} Once reconstituted, use immediately. 
Rekonstituirano zdravilo uporabite uporabite takoj.
First dose: Versican Plus Pi from 8-9 weeks of age Second dose: Versican Plus Pi mixed with Versiguard Rabies 3-4 weeks later, but not before 12 weeks of age. 
Prvi odmerek: Versican Plus Pi od starosti 8-9 tednov naprej Drugi odmerek: Versican Plus Pi zmešamo z Versiguard Rabies 3-4 tedne kasneje, toda ne pred starostjo 12 tednov.
Second dose: Versican Plus Pi mixed with Versiguard Rabies 3-4 weeks later, but not before 12 weeks of age. 
Drugi odmerek: Versican Plus Pi zmešamo z Versiguard Rabies 3-4 tedne kasneje, toda ne pred starostjo 12 tednov.
Primary vaccination scheme: Two doses of Versican Plus Pi 3-4 weeks apart from 6 weeks of age. 
Osnovno cepljenje: Dva odmerka Versican Plus Pi v razmaku 3-4 tednov od starosti 6 tednov naprej.
Once mixed, the contents of the vial should appear a whitish to yellowish colour with a slight opalescence. 
Po zmešanju mora vsebina viale izgledati belkasto do rumenkasto z rahlo opaloscenco.
Name and address of the manufacturer of the biological active substances 
Ime in naslov proizvajalca (proizvajalcev) biološke (bioloških) učinkovine (učinkovin) Bioveta, a.s.,
PACKAGE LEAFLET: Versican Plus Pi lyophilisate and solvent for suspension for injection for dogs 
Versican Plus Pi liofilizat in vehikel za suspenzijo za injiciranje za pse
Plastic box containing 25 vials (1 dose) of lyophilisate and 25 vials (1 ml) of solvent. 
Plastična škatla s 25 vialami (s po enim odmerkom) liofilizata in 25 vialami (po 1 ml) vehikla.
NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus Pi lyophilisate and solvent for suspension for injection for dogs 
NAVODILO ZA UPORABO Versican Plus Pi liofilizat in vehikel za suspenzijo za injiciranje za pse
No other adverse reactions other than those mentioned under “Adverse reactions” were observed after administration of a 10-fold overdose of the vaccine. 
Po dajanju 10-krat prevelikega odmerka cepiva ni bilo opaziti drugih neželenih učinkov, razen tistih, navedenih v poglavju »Neželeni učinki«.
Name and address of the manufacturer responsible for batch release 
Ime in naslov proizvajalca (proizvajalcev) zdravila, odgovornega (odgovornih) za sproščanje serij Bioveta, a.s.,
The contents of a single vial of Versican Plus Pi should be reconstituted with the contents of a single vial of Versiguard Rabies (instead of the solvent). 
Vsebino viale zdravila Versican Plus Pi je treba rekonstituirati z vsebino viale zdravila Versiguard
NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus Pi solvent for dogs 
Versican Plus Pi vehikel za pse
This procedure will involve removing the following recommendations and indications for which no data were provided: 
Ta postopek vključuje umik naslednjih priporočil in indikacij, za katere podatki niso bili predloženi:
o use in pigeons. 
o uporaba pri golobih.
In practice this means that in intensive systems all the birds in one house will be treated even though not all are exhibiting signs of disease. 
To v praksi pomeni, da se pri sistemih intenzivne reje zdravi vsa perutnina v eni hiši, čeprav vsa ne kažejo znakov bolezni.
o prevention and control of coccidiosis; 
o preprečevanje in nadzor kokcidioze,
Critical evaluation 
OSNOVNE INFORMACIJE
o repeat treatment can be administered after 5 days if infection is severe; 
o pri hudi okužbi se lahko zdravljenje ponovi po petih dneh,
The dose and duration of treatment in all Member States for chickens and turkeys is 7 mg/kg bodyweight per day for two consecutive days. 
Priporočeni odmerek in trajanje zdravljenja za piščance in purane je 7 mg/kg telesne mase na dan, in sicer dva zaporedna dneva.
However, it was noted that the indications, species and posology in the SPCs of some of the authorised products were different and these therefore need to be amended to bring them in line with the indications and dosing regimens used in the environmental risk assessment. 
Hkrati je bilo ugotovljeno, da se indikacije, živalske vrste in odmerjanje v povzetkih glavnih značilnosti za nekatera odobrena zdravila razlikujejo in jih je zato potrebno spremeniti, da bodo skladni s tisto indikacijo in režimom odmerjanja, ki sta bila uporabljena v oceni tveganja za okolje.
Germany considered that the authorisation of Baycox 2.5 % solution may present a potential serious risk to the environment on the following grounds: 
Nemčija je zadevo napotila na CVMP zaradi skrbi, da lahko toltrazuril pomeni morebitno resno tveganje za okolje in to iz naslednjih razlogov:
Toltrazuril is administered orally in the drinking water for the treatment of coccidiosis. 
Toltrazuril je derivat triazintriona, ki se daje peroralno v vodi za pitje pri zdravljenju kokcidioze pri piščancih in puranih.
It was therefore concluded that the marketing authorisations can be maintained without special warnings in point 5.3 (Environmental properties) of the SPC provided the product is used as indicated by the Marketing Authorisation Holders in their responses to questions by the Committee, i.e. a dose of 7 mg/kg bw on two consecutive days for the treatment of coccidiosis in chickens and turkeys. 
CVMP je zaključil, da lahko imetniki ohranijo dovoljenja za promet brez potrebe po posebnih opozorilih v točki 5.3 (Okoljski podatki) povzetka glavnih značilnosti zdravila (SPC), če se bo zdravilo uporabljalo pod dogovorjenimi pogoji, tj. odmerek 7 mg/kg telesne mase dva dni zapored za zdravljenje kokcidioze pri piščancih in puranih.
Baycox 2,5 % 
Stran 2/2
2794-003 Carnaxide 
EMEA/402698/2008-SL
The marketing authorisation is suspended on 12 June 2007 
Evropska komisija je odločbo izdala dne 26. septembra 2008.
However, there are changes required to the SPCs of some of the authorised products to bring them in line with the indications and dosing regimens used in the environmental risk assessment. 
Odbor je tudi predlagal da je treba ustrezna dovoljenja za promet z zdravilom spremeniti, da bi uskladili indikacije in režime odmerjanja s tistimi, ki so bili uporabljeni v oceni tveganja za okolje.
It will be replaced by Directive (2006/118/EC) which will come into force before 2013. 
Člen 35 Direktive 2001/82/ES, kakor je bil spremenjena.
Animal Health 
ODBOR ZA ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI (CVMP)
Litvinovska 609/3 190 21 Praha 9 
London, 26. septembra 2008 EMEA/402698/2008
ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS 
Seznam zadevnih imen zdravil je naveden v Dodatku I. Znanstveni zaključki so na voljo v Dodatku II, spremembe zadevnih poglavij povzetka glavnih značilnosti zdravila pa v Dodatku III.
The CVMP having considered the data provided and the scientific discussion within the Committee concluded that after administration of products containing toltrazuril to the target animal the dose is excreted as a mixture of parent compound and a major metabolite toltrazuril sulfone. 
CVMP je na svojem zasedanju julija 2008 ob upoštevanju vseh predloženih podatkov in znanstvene razprave soglasno sprejel mnenje, da je ovrednotenje tveganja, ki ga predstavljata toltrazuril in njegovi glavni presnovek, toltrazuril sulfon, za kopenske rastline in talno vodo, pokazalo, da je uporaba zdravil s toltrazurilom sprejemljiva.
However, in some Member States (Czech Republic, Hungary, Italy, The Netherlands, Portugal and the United Kingdom) administration can be repeated after five days in the face of severe challenge. 
Dovoljenja za promet z zdravili za uporabo v veterinarski medicini, ki vsebujejo toltrazuril in so namenjena za uporabo pri perutnini, so bila pred tem odobrena družbi Bayer HealthCare in/ali Ceva Santé Animale v Avstriji, Belgiji, Bolgariji, na Cipru, v Češki republiki, Franciji, Nemčiji, Grčiji, na Madžarskem, Irskem, v Italiji, na Poljskem, Portugalskem, v Romuniji, na Slovaškem, v Sloveniji, na Nizozemskem in v Združenem kraljestvu po nacionalnih postopkih za odobritev dovoljenja za promet z zdravilom.
Bayer Hungaria Kft.Co. 
Poročevalka je bila ga. R. Kearsley, soporočevalec pa g. G. J. Schefferlie.
It should be noted that a second course of treatment is not considered necessary as reported by Marketing Authorisation Holders. 
Arbitražni postopek se je začel 11. oktobra 2007 s sprejetjem seznama vprašanj, na katera morajo odgovoriti imetniki dovoljenja za promet.
The data submitted by the Marketing Authorisation Holders was only for chickens and turkeys. 
CVMP je predlagal ohranitev dovoljenj za promet z vsemi zdravili za uporabo v veterinarski medicini, ki vsebujejo toltrazuril in so namenjena za uporabo pri piščancih in puranih.
To assess the risk to human health consideration was given to the consumer safety evaluation with regards to residues of toltrazuril in food products of animal origin. 
• razširjena ocena tveganja na osnovi smernic Mednarodnega sodelovanja o uskladitvi tehničnih zahtev za registracijo zdravil za uporabo v veterinarski medicini (VICH) je jasno pokazala, da je treba pri zdravilih za uporabo v veterinarski medicini, ki vsebujejo toltrazuril in so namenjena za uporabo pri perutninskih živalskih vrstah, pričakovati, da bodo vplivala na okolje.
For the exposure assessment the equations according to the CVMP guideline (Environmental Impact Assessment for Veterinary Medicinal Products in support of the VICH guidelines GL6 and GL38 (EMEA/CVMP/ERA/418282/2005)) were used with modified parameters to reflect the actual use of toltrazuril. 
Dne 31. avgusta 2007 je Nemčija sprožila skupno napotitev po členu 35 Direktive 2001/82/ES, kakor je bila spremenjena, za nacionalno odobreno zdravilo Baycox 2,5 % (raztopina za perutnino).
The information provided stressed the importance of the product for use in cases where coccidiostats and vaccination had failed, given the limited availability of other treatments (amprolium, sulphonamides) and the need to rotate these treatments in order to avoid/postpone the development of resistance. 
Dne 10. oktobra 2007 je Evropska komisija odločila, da mora obseg napotitve vključevati vsa odobrena zdravila za uporabo v veterinarski medicini, ki vsebujejo toltrazuril (tj. referenčno zdravilo in generična zdravila, ki izvirajo iz tega) in so namenjena za uporabo pri perutninskih živalskih vrstah.
Responses to the CVMP list of questions containing the three points considered by the CVMP (as listed in the opinion) were received from Bayer HealthCare AH (Baycox) and Ceva Santé Animale (Cevazuril). 
CVMP se je na zasedanju od 11. do 13. decembra 2007 strinjal z dvomesečnim podaljšanjem roka za predložitev odgovorov na seznam vprašanj, ki ga je zahtevala družba Bayer HealthCare.
LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE VETERINARY MEDICINAL PRODUCTS, ANIMAL SPECIES, ROUTE(S) OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 
MNENJE V ZVEZI Z NAPOTITVIJO V SKLADU S ČLENOM 351 ZA VSA ODOBRENA ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI, KI VSEBUJEJO TOLTRAZURIL, NAMENJEN ZA UPORABO PRI PERUTNINI Mednarodno nelastniško ime (INN): Toltrazuril
Package size micrograms/0.5 ml 
Velikost pakiranja mikrogramov /0,5 ml
Solution for injection Subcutaneous use pre-filled syringe (glass) 
Raztopina za injiciranje Subkutana uporaba napolnjena injekcijska brizga (steklo)
Cartridge in a prefilled pen (250 micrograms/ 0.5 ml) 
Vložek v napolnjenem injekcijskem peresniku (250 mikrogramov /0,5 ml)
1 pre-filled pen + 1 needle 
1 napolnjen injekcijski peresnik + 1 igla
250 micrograms Solution for injection in pre-filled pen 
1 napolnjena injekcijska brizga mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku
Route of Administration 
Pot uporabe Ovojnina
In addition there was no evidence of unexpected safety concerns. 
Poleg tega ni dokazov za nepričakovane pomisleke glede varnosti.
The recommended dose is one tablet a day, taken with food. 
Priporočeni odmerek je ena tableta enkrat dnevno, zaužita s hrano.
What measures are being taken to ensure the safe and effective use of Rezolsta? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Rezolsta?
Rezolsta darunavir / cobicistat 
Rezolsta darunavir/kobicistat
Other information about Rezolsta 
Druge informacije o zdravilu Rezolsta
Overall, 258 patients (82%) achieved this response after 24 weeks of treatment, and 253 patients (81%) at 48 weeks, which was comparable to results previously seen with darunavir plus ritonavir. 
Po24 tednih zdravljenja je tak odziv skupno doseglo 258 bolnikov (82 %), po 48 tednih pa 253 bolnikov (81 %), kar je primerljivo s predhodno zabeleženimi rezultati za uporabo darunavirja v kombinaciji z ritonavirjem.
The full EPAR and risk management plan summary for Rezolsta can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Rezolsta sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What benefits of Rezolsta have been shown in studies? 
Kakšne koristi je zdravilo Rezolsta izkazalo v študijah?
Effectiveness was measured by a reduction in viral load (the amount of HIV-1 virus in the blood) to less than 50 copies/ml. 
Učinkovitost so merili glede na zmanjšanje virusnega bremena (količine virusa HIV-1 v krvi) na manj kot 50 kopij/ml.
It is not intended to provide practical advice on how to use Rezolsta. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
This is a summary of the European public assessment report (EPAR) for Rezolsta. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Rezolsta.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Rezolsta's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Rezolsta večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
Rezolsta is available as tablets that contain 800 mg of darunavir and 150 mg of cobicistat. 
Zdravilo Rezolsta je na voljo v obliki tablet, ki vsebujejo 800 mg darunavirja in 150 mg kobicistata.
Why is Rezolsta approved? 
Zakaj je bilo zdravilo Rezolsta odobreno?
What are the risks associated with Rezolsta? 
Kakšna tveganja so povezana z zdravilom Rezolsta?
Darunavir is a protease inhibitor. 
Darunavir je zaviralec proteaze.
A risk management plan has been developed to ensure that Rezolsta is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Rezolsta je bil pripravljen načrt obvladovanja tveganj.
When the enzyme is blocked, the virus does not reproduce normally and its increase and spread slows down. 
Kadar je encim blokiran, se virus ne razmnožuje normalno, kar upočasni naraščanje količine virusa in njegovo širjenje.
It must also not be used together with certain other medicines as it may interact with them, thereby reducing the effectiveness of treatment or increasing the risk of side effects. 
Prav tako se ne sme uporabljati z nekaterimi drugimi zdravili, saj lahko pride do njihovega medsebojnega delovanja, zaradi česar se zmanjša učinkovitost zdravljenja ali poveča tveganje neželenih učinkov.
What is Rezolsta and what is it used for? 
Kaj je zdravilo Rezolsta in za kaj se uporablja?
The most serious side effects were rash, diabetes, hypersensitivity (allergic) reactions, vomiting, and ‘immune reconstitution syndrome'. 
Najresnejši neželeni učinki so bili izpuščaji, sladkorna bolezen, preobčutljivostne (alergijske) reakcije, bruhanje in „sindrom imunske obnove“.
It blocks an enzyme called protease, which the HIV virus needs to make new copies of itself. 
Zavira encim, imenovan proteaza, ki ga virus HIV potrebuje za podvajanje.
Both active substances have already been shown to be effective, and combining them into a single tablet was considered to be more convenient than taking them separately, reducing the risk of errors. 
Za obe zdravilni učinkovini je bila učinkovitost že dokazana, njihova združitev v eno samo tableto pa je bila ocenjena kot bolj priročna kot njuno ločeno jemanje, saj se tako zmanjša tveganje napak.
Rezolsta contains two active substances. 
Zdravilo Rezolsta vsebuje dve zdravilni učinkovini.
Rezolsta, taken in combination with other HIV medicines, reduces the amount of HIV in the blood and keeps it at a low level. 
Zdravilo Rezolsta v kombinaciji z drugimi zdravili proti virusu HIV zmanjša količino virusa HIV v krvi in jo ohranja na nizki ravni.